GAM Holding AG Invests $2.24 Million in Teladoc Health Inc (NYSE:TDOC)

GAM Holding AG purchased a new position in Teladoc Health Inc (NYSE:TDOC) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 40,346 shares of the health services provider’s stock, valued at approximately $2,243,000. GAM Holding AG owned 0.06% of Teladoc Health as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc lifted its position in shares of Teladoc Health by 26.9% during the 3rd quarter. Vanguard Group Inc now owns 5,874,182 shares of the health services provider’s stock valued at $507,236,000 after acquiring an additional 1,244,388 shares during the period. Janus Henderson Group PLC lifted its position in shares of Teladoc Health by 87.2% during the 1st quarter. Janus Henderson Group PLC now owns 2,989,090 shares of the health services provider’s stock valued at $166,197,000 after acquiring an additional 1,391,969 shares during the period. Riverbridge Partners LLC lifted its position in shares of Teladoc Health by 24.0% during the 1st quarter. Riverbridge Partners LLC now owns 1,523,561 shares of the health services provider’s stock valued at $84,710,000 after acquiring an additional 294,523 shares during the period. Macquarie Group Ltd. lifted its position in shares of Teladoc Health by 101.5% during the 4th quarter. Macquarie Group Ltd. now owns 1,125,275 shares of the health services provider’s stock valued at $55,780,000 after acquiring an additional 566,839 shares during the period. Finally, Bellevue Group AG lifted its position in shares of Teladoc Health by 83.1% during the 4th quarter. Bellevue Group AG now owns 1,073,839 shares of the health services provider’s stock valued at $53,230,000 after acquiring an additional 487,319 shares during the period.

A number of research analysts recently issued reports on TDOC shares. Zacks Investment Research upgraded shares of Teladoc Health from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Guggenheim initiated coverage on shares of Teladoc Health in a research note on Wednesday, April 17th. They set a “buy” rating for the company. ValuEngine lowered shares of Teladoc Health from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 14th. Bank of America initiated coverage on shares of Teladoc Health in a research note on Thursday, June 13th. They set a “buy” rating and a $65.00 price target for the company. Finally, Craig Hallum restated a “buy” rating and set a $70.00 price target (down previously from $80.00) on shares of Teladoc Health in a research note on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Teladoc Health presently has a consensus rating of “Buy” and an average price target of $82.68.

In related news, President Peter A. Mcclennen sold 8,359 shares of the stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $60.02, for a total transaction of $501,707.18. Following the completion of the transaction, the president now owns 11,400 shares in the company, valued at $684,228. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Jason N. Gorevic sold 30,000 shares of the stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $53.04, for a total transaction of $1,591,200.00. Following the transaction, the chief executive officer now owns 673,924 shares of the company’s stock, valued at approximately $35,744,928.96. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 144,542 shares of company stock valued at $8,285,951. 3.95% of the stock is owned by company insiders.

Shares of NYSE TDOC traded up $3.59 during trading on Friday, hitting $66.41. The stock had a trading volume of 2,741,175 shares, compared to its average volume of 993,611. Teladoc Health Inc has a 12 month low of $42.08 and a 12 month high of $89.05. The company has a quick ratio of 7.54, a current ratio of 7.54 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $4.75 billion, a P/E ratio of -46.12 and a beta of 1.26. The company’s fifty day moving average price is $59.71.

Teladoc Health (NYSE:TDOC) last posted its earnings results on Tuesday, April 30th. The health services provider reported ($0.43) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.44) by $0.01. The firm had revenue of $128.57 million during the quarter, compared to analyst estimates of $127.99 million. Teladoc Health had a negative net margin of 22.63% and a negative return on equity of 10.86%. The business’s revenue was up 43.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.39) EPS. On average, research analysts predict that Teladoc Health Inc will post -1.53 earnings per share for the current year.

Teladoc Health Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

See Also: Investing strategies using the yield curve

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.